OSCR
Oscar Health, Inc.
OSCR offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
STX
Seagate Technology Holdings plc
STX has the edge over OSCR overall, supported by stronger modeled upside and lower modeled downside.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
STX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
STX's revenue, profitability, cash flow and balance sheet are all currently strong.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over STX in the historical PE scenario, which offers more potential upside but is not a forecast.
STX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.9x | $188 | -65% |
| Forward | 12x | $545 | — |
| Fair | 17x | $318 | -42% |
| Current | 29x | $545 | — |
| Expensive | 43x | $823 | +51% |
Historical ranges are pointers, not guarantees.
STX's PE is in its expensive range at 29x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
STX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for STX, with profitability improving.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
STX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.99 | +147% |
| Q3 2026 | $19.06 | +145% |
| Q2 2026 | $13.90 | +105% |
| Q1 2026 | $10.54 | +51% |
| Q4 2025 | $8.84 | +60% |
| Q3 2025 | $7.79 | +101% |
| Q2 2025 | $6.77 | +328% |
| Q1 2025 | $6.96 | +$8.26 |
| Q4 2024 | $5.51 | +$9.02 |
STX has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over STX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
STX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.2B | +61% |
| Q2 2026 | $3.6B | +48% |
| Q1 2026 | $3.1B | +44% |
| Q4 2025 | $2.8B | +22% |
| Q3 2025 | $2.6B | +21% |
| Q2 2025 | $2.4B | +30% |
| Q1 2025 | $2.2B | +31% |
| Q4 2024 | $2.3B | +50% |
STX's revenue has grown year over year for 10 quarters in a row: $4.2B last quarter, up 61% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 49% | +22 points |
| Q2 2026 | 43% | +20 points |
| Q1 2026 | 32% | +12 points |
| Q4 2025 | 30% | +8.9 points |
| Q3 2025 | 26% | +7.8 points |
| Q2 2025 | 23% | +6.6 points |
| Q1 2025 | 20% | +11 points |
| Q4 2024 | 21% | +13 points |
STX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
STX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +246% |
| Q2 2026 | $1.1B | +163% |
| Q1 2026 | $953M | +341% |
| Q4 2025 | $607M | +305% |
| Q3 2025 | $427M | +1481% |
| Q2 2025 | $425M | +12% |
| Q1 2025 | $216M | +69% |
| Q4 2024 | $150M | +52% |
STX has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
STX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +3M shares |
| 1 year | +2.7% | +6M shares |
| 3 years | +12% | +24M shares |
| 5 years | +0.4% | +1M shares |
| Available history | -12% | -33M shares |
STX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $400M |
| Q2 2026 | $117M |
| Q1 2026 | $30M |
| Q4 2025 | — |
| Q3 2025 | $29M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
STX spent $547M buying back its own shares over the past year.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over STX on leverage, with a lower net debt burden relative to earnings.
STX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.2x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.8x | Moderate |
STX's net debt is less than a year of its operating earnings (EBITDA), down from 1.6 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
STX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 8.3 | Oversold |
STX's weekly RSI is 40 (neutral) and its Stochastic is 8 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over STX on valuation relative to its sector.
STX PE vs Technology Sector
| Metric | STX | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 28x | 2.7% above |
| PE % | 75 | 35 | 40 pts above |
STX is trading at 29x earnings, in line with the Technology sector's median of 28x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over STX on trend strength, trading above more of its moving averages.
STX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $683.6 | 20% below |
| 20 week MA | $785.0 | 31% below |
| 50 week MA | $630.7 | 14% below |
| 100 week MA | $387.3 | 41% above |
| 200 week MA | $234.4 | 133% above |
STX has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 133% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over STX on returns for 2026, with the stronger performance.
STX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $59.6 | $63.0 | +5.7% |
| 2021 | $63.0 | $111.4 | +77% |
| 2022 | $111.4 | $50.5 | -55% |
| 2023 | $50.5 | $85.4 | +69% |
| 2024 | $85.4 | $87.4 | +2.4% |
| 2025 | $87.4 | $286.2 | +228% |
| 2026 YTD | $286.2 | $545.1 | +90% |
STX's yearly returns have swung widely, from +228% in 2025 to −55% in 2022. It's up 90% so far in 2026.